about
Recent insights in nanotechnology-based drugs and formulations designed for effective anti-cancer therapyQuantum dots as a platform for nanoparticle drug delivery vehicle designDirect cytosolic delivery of siRNA using nanoparticle-stabilized nanocapsulesTargeting SR-BI for Cancer Diagnostics, Imaging and TherapyLipid-Based Nanocarriers for RNA DeliveryAdvancements in the delivery of epigenetic drugsLipid-based vectors for siRNA deliveryStimuli-Responsive Materials for Controlled Release of Theranostic Agents.The siRNA targeted to mdr1b and mdr1a mRNAs in vivo sensitizes murine lymphosarcoma to chemotherapyRibonucleotide Reductase Requires Subunit Switching in Hypoxia to Maintain DNA ReplicationTargeted siRNA delivery reduces nitric oxide mediated cell death after spinal cord injuryImmunoliposomal systems targeting primary effusion lymphoma: in vitro study.Versatile RNA interference nanoplatform for systemic delivery of RNAs.Hydrolytic charge-reversal of PEGylated polyplexes enhances intracellular un-packaging and activity of siRNANanoparticle-mediated systemic delivery of siRNA for treatment of cancers and viral infections.Down regulation of BCL11B expression inhibits proliferation and induces apoptosis in malignant T cells by BCL11B-935-siRNA.Modulating pharmacokinetics, tumor uptake and biodistribution by engineered nanoparticlesRecent advances in diagnosis and treatment of gliomas using chlorotoxin-based bioconjugates.Non-viral nanocarriers for siRNA delivery in breast cancer.Efficient and targeted delivery of siRNA in vivo.Superparamagnetic iron oxide nanoparticle-based delivery systems for biotherapeuticsCo-delivery of doxorubicin and Bmi1 siRNA by folate receptor targeted liposomes exhibits enhanced anti-tumor effects in vitro and in vivo.Delivery of siRNA therapeutics: barriers and carriers.Analysis of the expression pattern of the BCL11B gene and its relatives in patients with T-cell acute lymphoblastic leukemiaTargeted delivery of siRNA to hepatocytes and hepatic stellate cells by bioconjugationEnhanced cytotoxicity for colon 26 cells using doxorubicin-loaded sorbitan monooleate (Span 80) vesiclesTargeted siRNA delivery by anti-HER2 antibody-modified nanoparticles of mPEG-chitosan diblock copolymer.Liposome-coated lipoplex-based carrier for antisense oligonucleotides.Porous silicon microparticles for delivery of siRNA therapeutics.Development of small interfering RNA delivery system using PEI-PEG-APRPG polymer for antiangiogenic vascular endothelial growth factor tumor-targeted therapy.Synthetic poly(ester amine) and poly(amido amine) nanoparticles for efficient DNA and siRNA delivery to human endothelial cellsSilencing β3 Integrin by Targeted ECO/siRNA Nanoparticles Inhibits EMT and Metastasis of Triple-Negative Breast Cancer.Microfluidic synthesis of rigid nanovesicles for hydrophilic reagents deliveryCarbon nanotubes part II: a remarkable carrier for drug and gene deliveryDelivery of DNAzyme targeting aurora kinase A to inhibit the proliferation and migration of human prostate cancer.Systemic siRNA Nanoparticle-Based Drugs Combined with Radiofrequency Ablation for Cancer Therapy.Transarterial chemoembolization of hepatocellular carcinoma in a rat model: the effect of additional injection of survivin siRNA to the treatment protocolGlutamine-chitosan modified calcium phosphate nanoparticles for efficient siRNA delivery and osteogenic differentiation.Paclitaxel tumor priming promotes delivery and transfection of intravenous lipid-siRNA in pancreatic tumors.pH-Sensitive carboxymethyl chitosan-modified cationic liposomes for sorafenib and siRNA co-delivery.
P2860
Q26745710-039B0604-8EBF-4EEB-B606-62F5E14ECFF5Q26996556-363732AE-0A7A-4FF2-91E9-68805B1FA23EQ27339704-877F09E7-50BF-45C7-ABAF-1A22AD6BDB16Q28066708-A56342A2-5618-45C1-A817-D7CEFC75D05DQ28080706-ABB484EC-E814-4593-B179-1024D4D7687BQ28088478-60E93821-C82F-477E-B120-473C574E833BQ28828356-78CD0F9B-5333-400E-996F-05A36DB97256Q30406730-B9E85954-A568-4F1E-95EF-C4E0BA30113CQ33578222-28E67A34-FF63-48DA-A1B2-455D770FA92DQ33603402-C1F87408-ECB6-4E93-9325-73F90A02A09AQ33651175-2CF82C60-09AE-4041-8ADE-73E745F67B8AQ33704280-FD0CDD29-407E-4D3D-98A1-DCAC1382B8C7Q33716038-84BF0776-A761-44B6-BF62-1FD1AE5D8DFBQ33918054-2D478303-3050-4511-9FEB-06FE3DACBDC9Q33935474-1D580E03-FBAE-44BE-890D-38941B461DE0Q33960952-F36C9241-F026-487B-994C-832E2C8BDF33Q34023451-D637EDA7-4DE8-4175-8F0F-873613F61163Q34066507-933168A6-E28A-4C42-8E8B-4A3BBAAB72D8Q34079608-3F7678BC-FA30-4E63-9F1D-916D3F1311B9Q34149828-3476B150-DC41-479A-9AF9-652346431A86Q34205366-E4F2B71D-BF3F-4CA5-BE3C-1C535C242188Q34237712-1EE72D19-B6B1-4CB2-A527-B7D20ACCAB54Q34293708-576E9215-2211-400B-B947-096F20D28E2AQ34353401-3E3B3E9B-1356-483C-A658-BF62F87D7177Q34389283-D8F6667F-46EC-4847-A974-92E790BA941FQ34587836-E614D6A7-0BB7-439A-AF2B-2FDF8477FF7BQ34742858-DF5BA604-6DF1-41CE-88C8-320BB24A64A1Q35087432-A21CF95B-FBA1-4F6E-833E-6F60DFD45D65Q35161952-3F097FE2-C6A4-4756-8A75-C2FACC0B5C4FQ35179033-36F69C07-FDF9-496C-AC71-C44BA2EA3DDEQ35656914-CDCCF677-64B1-4069-95BF-09ECB548E9FAQ35674830-2347696E-B0D3-4DFA-874B-B4A221F0553FQ35753701-741C75CA-DBE2-42DB-8ED2-E7E1613B8649Q35762812-7B77AC5D-B01D-419D-A033-2EAF1A7EAAF7Q35794644-155BEF21-D0CD-4412-BDFC-D72A347C9701Q35831738-90397ADA-EAEE-4559-A9C8-76FFF828FB08Q36027056-E75CEA55-B4FD-43E3-B025-DBB520047891Q36092151-E71088BA-2DCF-4CA8-AECF-4B61C4A54227Q36092777-46DA66FA-2F11-4CC6-8C41-4B8A22AF16B5Q36137279-4D53E447-B9DF-4A06-B535-1D9F7818E12D
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 05 May 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
siRNA delivery systems for cancer treatment.
@en
siRNA delivery systems for cancer treatment.
@nl
type
label
siRNA delivery systems for cancer treatment.
@en
siRNA delivery systems for cancer treatment.
@nl
prefLabel
siRNA delivery systems for cancer treatment.
@en
siRNA delivery systems for cancer treatment.
@nl
P1476
siRNA delivery systems for cancer treatment.
@en
P2093
Tae Gwan Park
Yu-Kyoung Oh
P304
P356
10.1016/J.ADDR.2009.04.018
P407
P577
2009-05-05T00:00:00Z